Evidence map›Paper›PMID 39480524›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Differential uptake of arginine derivatives by the human heteromeric amino acid transporter b

Sofna Banjarnahor, Lorenz A Scherpinski, Max Keller, Jörg König, Renke Maas

Abstract read
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sofna BanjarnahorInstitute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054, Erlangen, Germany.
Lorenz A ScherpinskiInstitute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054, Erlangen, Germany.
Max KellerInstitute of Pharmacy, Universität Regensburg, 93040, Regensburg, Germany.
Jörg KönigInstitute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054, Erlangen, Germany.
Renke MaasInstitute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054, Erlangen, Germany. Renke.Maas@fau.de.

Funding

Deutsche Forschungsgemeinschaft (DFG) KO 2120/10-1Deutsche Forschungsgemeinschaft (DFG) MA 3324/7-1
6 · The paper itself

Abstract

L-arginine and its (patho-)physiologically active derivatives, L-homoarginine and asymmetric dimethylarginine (ADMA), show significant differences in their renal clearance. The underlying molecular mechanisms remain to be elucidated, but selective tubular transport protein-mediated mechanisms likely play a role. In the present study, we investigate the human heteromeric transporter b

Indexed as

Amino Acid Transport Systems, BasicArginineHomoarginineAnimalsBiological TransportDogsHumansMadin Darby Canine Kidney CellsAmino Acid Transport Systems, BasicArginineHomoarginineN,N-dimethylarginineADMAb0,+AT-rBATL-arginineL-homoarginineProximal tubuleSLC3A1SLC7A9Transport

Identifiers

PMID39480524
PMCPMC11978698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.